SSY GROUP (02005.HK) saw its stock price plummet 5.41% in Thursday's trading session following the release of its disappointing interim results for 2025. The pharmaceutical company reported a significant decline in both revenue and profit, reflecting challenging market conditions and policy changes in the industry.

According to the interim report, SSY GROUP's sales revenue for the first half of 2025 fell to approximately HK$2.147 billion, marking a substantial 35.7% decrease compared to the same period last year. More alarmingly, the profit attributable to equity holders plunged by 58.7% year-on-year to approximately HK$283.5 million. The company's earnings per share stood at HK$0.0962, and it declared an interim dividend of HK$0.05 per share.

The main factor contributing to the company's underwhelming performance was the struggle in its core IV solution business. SSY GROUP faced significant pressure due to changes in the industrial policy environment and weak market demand. Both production and sales volumes of IV solutions showed marked declines, with sales volume dropping 37% year-on-year to approximately 715 million bottles (bags), and sales revenue decreasing by 45% to HK$1.199 billion. While some segments, such as blood filtration products and certain oral preparations, showed growth, these gains were not sufficient to offset the overall decline in the company's performance. The stark contrast between the current results and previous year's performance likely triggered the sharp sell-off in SSY GROUP's stock.